cyc 202 has been researched along with carboplatin in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, MK; Sharma, A | 1 |
| Butler-Manuel, S; Chivers, P; Coley, HM; Crook, T; Giannopoulos, T; Lovell, DP; Madhuri, K; Papacharalbous, E; Safuwan, NA | 1 |
2 other study(ies) available for cyc 202 and carboplatin
| Article | Year |
|---|---|
Enhancement of carboplatin- and quercetin-induced cell death by roscovitine is Akt dependent and p53 independent in hepatoma cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Carboplatin; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; Cell Survival; Down-Regulation; Fluorouracil; Hep G2 Cells; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Purines; Quercetin; Roscovitine; Signal Transduction; Tumor Suppressor Protein p53 | 2011 |
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Ovarian Neoplasms; Purines; Roscovitine | 2012 |